Eight years after a landmark buyout, Sanofi agrees to pay aggrieved Genzyme shareholders $315M to settle foot-dragging claims
Sanofi’s $20 billion deal to buy Genzyme in early 2011 qualifies as one of the smartest M&A pacts in industry history, netting a blockbuster MS drug franchise that still delivers billions to the pharma giant.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.